Sanofi SA ACTRIMS Investor Call Transcript
Good morning and good afternoon to everyone. I'm Felix Lauscher, with Sanofi Investor Relations. Welcome to today's Sanofi and neurology event, which coincides with the ACTRIMS forum 2022 in West Palm Beach, Florida. We are looking forward to spending the next hour with you to review and discuss recent data for tolebrutinib and to share more information about our broader neurology portfolio.
Moving to Slide 3. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.
Now turning to Slide 4. We will start with a presentation followed by a Q&A session. Let me now turn the call over to Dietmar Berger, Global Head of Development and Chief Medical Officer at Sanofi. Dietmar?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
